Advertisement
Heart, Lung and Circulation

Catheter Ablation for Atrial Fibrillation: Are We Isolating Our Most Vulnerable Patients?

  • Kasun De Silva
    Affiliations
    Department of Cardiology, Westmead Hospital, Sydney, NSW, Australia

    Westmead Applied Research Centre, University of Sydney, Sydney, NSW, Australia
    Search for articles by this author
  • Saurabh Kumar
    Correspondence
    Corresponding author at: Associate Professor Saurabh Kumar, Department of Cardiology, Westmead Hospital, Westmead Applied Research Centre, University of Sydney, Darcy Road, Westmead, NSW, Australia, 2145
    Affiliations
    Department of Cardiology, Westmead Hospital, Sydney, NSW, Australia

    Westmead Applied Research Centre, University of Sydney, Sydney, NSW, Australia
    Search for articles by this author
      A central tenant of the health care system in Australia, which is based on a hybrid public-private model underpinned by the mandatory public insurance scheme of Medicare, is equitable access and affordable health care for all [
      • Dixit S.K.
      • Sambasivan M.
      ]. Medicare provides universal basic health care coverage to citizens, permanent residents, and refugees. Over and above this, private health insurance offers the opportunity to individuals to expand their health care coverage including the ability to choose their treating physicians, location of care and faster access to care in the form of shorter waiting lists through private hospitals. As of 2019–20, there are 695 public hospitals in Australia and 657 private hospitals [
      Australian Institute of Health and Welfare
      Australia’s health 2022: in brief. 2022; catalogue number AUS241, Australia’s health series number 18.
      ]. Of the 11.1 million hospitalisations in 2019–20, 6.7 million were in the public system and 4.4 million were private [
      Australian Institute of Health and Welfare
      Australia’s health 2022: in brief. 2022; catalogue number AUS241, Australia’s health series number 18.
      ]. Data examining equity of access for crucial health care procedures is a vital marker of health system performance.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Heart, Lung and Circulation
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Dixit S.K.
        • Sambasivan M.
        A review of the Australian healthcare system: a policy perspective. SAGE Open Med, 2018 (6:2050312118769211)
        • Australian Institute of Health and Welfare
        Australia’s health 2022: in brief. 2022; catalogue number AUS241, Australia’s health series number 18.
        ([accessed 27/7/22])
        • Lippi G.
        • Sanchis-Gomar F.
        • Cervellin G.
        Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge.
        Int J Stroke. 2021; 16: 217-221
        • de Denus S.
        • Sanoski C.A.
        • Carlsson J.
        • Opolski G.
        • Spinler S.A.
        Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis.
        Arch Intern Med. 2005; 165: 258-262
        • Packer D.L.
        • Piccini J.P.
        • Monahan K.H.
        • Al-Khalidi H.R.
        • Silverstein A.P.
        • Noseworthy P.A.
        • et al.
        Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial.
        Circulation. 2021; 143: 1377-1390
        • Kirchhof P.
        • Camm A.J.
        • Goette A.
        • Brandes A.
        • Eckardt L.
        • Elvan A.
        • et al.
        Early rhythm-control therapy in patients with atrial fibrillation.
        N Engl J Med. 2020; 383: 1305-1316
        • Sørensen S.K.
        • Johannessen A.
        • Worck R.
        • Hansen M.L.
        • Hansen J.
        Radiofrequency versus cryoballoon catheter ablation for paroxysmal atrial fibrillation: durability of pulmonary vein isolation and effect on atrial fibrillation burden: the RACE-AF randomized controlled trial.
        Circ Arrhyth Electrophysiol. 2021; 14e009573
        • Blomström-Lundqvist C.
        • Gizurarson S.
        • Schwieler J.
        • Jensen S.M.
        • Bergfeldt L.
        • Kennebäck G.
        • et al.
        Effect of catheter ablation vs antiarrhythmic medication on quality of life in patients with atrial fibrillation: the CAPTAF randomized clinical trial.
        JAMA. 2019; 321: 1059-1068
        • McKenna C.
        • Palmer S.
        • Rodgers M.
        • Chambers D.
        • Hawkins N.
        • Golder S.
        • et al.
        Cost-effectiveness of radiofrequency catheter ablation for the treatment of atrial fibrillation in the United Kingdom.
        Heart. 2009; 95: 542-549
        • Wazni O.M.
        • Dandamudi G.
        • Sood N.
        • Hoyt R.
        • Tyler J.
        • Durrani S.
        • et al.
        Cryoballoon ablation as initial therapy for atrial fibrillation.
        N Engl J Med. 2021; 384: 316-324
        • Andrade J.G.
        • Wells G.A.
        • Deyell M.W.
        • Bennett M.
        • Essebag V.
        • Champagne J.
        • et al.
        Cryoablation or drug therapy for initial treatment of atrial fibrillation.
        N Engl J Med. 2021; 384: 305-315
        • Kuniss M.
        • Pavlovic N.
        • Velagic V.
        • Hermida J.S.
        • Healey S.
        • Arena G.
        • et al.
        Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation.
        Europace. 2021; 23: 1033-1041
        • Turagam M.K.
        • Musikantow D.
        • Whang W.
        • Koruth J.S.
        • Miller M.A.
        • Langan M.-N.
        • et al.
        Assessment of catheter ablation or antiarrhythmic drugs for first-line therapy of atrial fibrillation: a meta-analysis of randomized clinical trials.
        JAMA Cardiol. 2021; 6: 697-705
        • Quiroz J.C.
        • Brieger D.
        • Jorm L.R.
        • Sy R.W.
        • Falster M.O.
        • Gallego B.
        An observational study of clinical and health system factors associated with catheter ablation and early ablation treatment for atrial fibrillation in Australia.
        Heart Lung Circ. 2022; 31: 1269-1276
        • Kummer B.R.
        • Bhave P.D.
        • Merkler A.E.
        • Gialdini G.
        • Okin P.M.
        • Kamel H.
        Demographic differences in catheter ablation after hospital presentation with symptomatic atrial fibrillation.
        J Am Heart Assoc. 2015; 4e002097
        • Olsen F.
        • Uleberg B.
        • Jacobsen B.K.
        • Heuch I.
        • Tande P.M.
        • Bugge E.
        • et al.
        Socioeconomic and geographic differences in ablation of atrial fibrillation in Norway-a national cohort study.
        BMC Public Health. 2022; 22: 303
        • Friberg L.
        • Tabrizi F.
        • Englund A.
        Catheter ablation for atrial fibrillation is associated with lower incidence of stroke and death: data from Swedish health registries.
        Eur Heart J. 2016; 37: 2478-2487
        • Brieger D.
        • Amerena J.
        • Attia J.R.
        • Bajorek B.
        • Chan K.H.
        • Connell C.
        • et al.
        National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018.
        Med J Aust. 2018; 209: 356-362
        • Fuster V.
        • Rydén L.E.
        • Cannom D.S.
        • Crijns H.J.
        • Curtis A.B.
        • Ellenbogen K.A.
        • et al.
        ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.
        Europace. 2006; 8: 651-745
        • January C.T.
        • Wann L.S.
        • Alpert J.S.
        • Calkins H.
        • Cigarroa J.E.
        • Cleveland J.C.
        • et al.
        2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.
        J Am Coll Cardiol. 2014; 64: e1-e76
        • Camm A.J.
        • Naccarelli G.V.
        • Mittal S.
        • Crijns H.J.
        • Hohnloser S.H.
        • Ma C.-S.
        • et al.
        The Increasing Role of Rhythm Control in Patients With Atrial Fibrillation: JACC State-of-the-Art Review.
        J Am Coll Cardiol. 2022; 79: 1932-1948
        • Gurusamy V.K.
        • Brobert G.
        • Vora P.
        • Friberg L.
        Sociodemographic factors and choice of oral anticoagulant in patients with non-valvular atrial fibrillation in Sweden: a population-based cross-sectional study using data from national registers.
        BMC Cardiovasc Disord. 2019; 19: 1-6
        • Hagengaard L.
        • Andersen M.P.
        • Polcwiartek C.
        • Larsen J.M.
        • Larsen M.L.
        • Skals R.K.
        • et al.
        Socioeconomic differences in outcomes after hospital admission for atrial fibrillation or flutter.
        Eur Heart J Qual Care Clin Outcomes. 2021; 7: 295-303
        • Cressman A.M.
        • Macdonald E.M.
        • Yao Z.
        • Austin P.C.
        • Gomes T.
        • Paterson J.M.
        • et al.
        Socioeconomic status and risk of hemorrhage during warfarin therapy for atrial fibrillation: a population-based study.
        Am Heart J. 2015; 170: 133-140 e3
        • Essien U.R.
        • Kornej J.
        • Johnson A.E.
        • Schulson L.B.
        • Benjamin E.J.
        • Magnani J.W.
        Social determinants of atrial fibrillation.
        Nat Rev Cardiol. 2021; 18: 763-773
        • Al-Busaidi I.S.
        • Clare G.C.
        • Joyce L.R.
        • Pearson S.
        • Lainchbury J.
        • Than M.
        • et al.
        Presentation, treatment and long-term outcomes of a multidisciplinary acute atrial fibrillation pathway: a 12-month follow-up study.
        Heart Lung Circ. 2022; 31: 216-223

      Linked Article